Regenerative med-tech Tissue Regenix (LON:TRX) will display nine poster presentations for its Dermapure skin graft product at the prestigious Symposium on Advanced Wound Care (SAWC) in Atlanta in April.
The posters were written by opinion leaders in the field and selected by a peer review committee.
Topics will include clinical efficacy in various types of wounds, pain reduction, a retrospective analysis of clinical outcomes and an analysis of DermaPure's extra-cellular matrix.
DermaPure, launched in the US in 2014, has been used to treat injuries ranging from diabetic or pressure ulcers through to frostbite, with total sales just passing US$1mln.
Greg Bila, the president of Tissue Regenix susbidiary Wound Care Inc said: "We are extremely proud of how DermaPure has performed within a competitive marketplace since it was launched in 2014.
“Having nine posters chosen by a peer review committee to appear at SAWC, I think, illustrates a deeper understanding and appreciation of the dCELL technology platform, and the difference that a product like DermaPure can make to patient treatment and recovery.”
Tissue Regenix’s dCELL technology removes DNA and other cellular material from animal and human tissue, but leaves an acellular tissue scaffold that can be populated by a patient’s own cells.